Boston Scientific Announces First Implant Of New Device To Treat Heart Failure
When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. The COGNIS CRT-D is designed to eliminate those compromises.
"The COGNIS CRT-D, even with its small size, offers extended longevity and a number of new features that will help me manage my heart failure patients," said Dr. Siegmund Winter, Elisabethinen Linz, Linz, Austria. "For example, the SmartDelay feature quickly proposes programmable device settings, which enables me to tailor individualised pacing therapy for my patients."
The COGNIS CRT-D is among the world's smallest and thinnest high-energy devices at 32.5 cc, while less than 10 mm thick. It offers features based on significant engineering advances, including extended battery longevity, self-correcting software and improved programming technology. The COGNIS CRT-D also offers SafetyCore™, a feature that in the unlikely event of a system error provides lifesaving shock therapy and basic pacing functionality.
Key features of the COGNIS CRT-D include:
- Bi-V Trigger: helps physicians manage heart failure patients with frequent atrial arrhythmias
- Electronic Repositioning™: provides physicians with the ability to electronically select between six different configurations for stimulating the left side of the heart even after implant, which may help avoid an additional surgical procedure
- Left Ventricle only pacing: this feature provides physicians with an additional pacing option for CRT patients
"Our CRM team is refocused on delivering therapy systems that meet clinician needs for safety, reliability and better patient outcomes," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We have re-engineered the way we design, build, test and report on our technology. The COGNIS CRT-D is a testament to the revitalisation of our CRM business and is one of many new products we plan to launch in 2008."
The first implants were performed by the following physicians:
- Dr. Siegmund Winter, Elisabethinen Linz, Linz, Austria
- Prof. Rik Willems, UZ Leuven, Leuven, Belgium
- Dr. med. Poul-Erik Bloch-Thomson, Gentofte Hospital, Hellerup, Denmark
- Dr. Jochem Stockinger, Herzzentrum Bad Krozingen, Bad Krozingen, Germany
- OA Dr. Johannes Sperzel, Kerckhoff-Klinik Bad Nauheim, Bad Nauheim, Germany
- OA Dr. med. Claudius Hansen, Klinikum Kassel, Kassel, Germany
- Prof. Dr. med. Bernd Lemke, Klinikum Lüdenscheid, Lüdenscheid, Germany
- PD Dr. med. Rainer Gradaus, Uniklinikum Münster, Münster, Germany
- Dr. Lieselotte van Erven, Leiden University Medical Center, Leiden, The Netherlands
- Dr. Luis Mont i Girbau, Hospital ClÃnic de Barcelona, Barcelona, Spain
- Dr. Ignacio GarcÃa Bolao, ClÃnica Universitaria de Navarra, Pamplona, Spain
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific-international.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, new product launches, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialise, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Boston Scientific Corporation
Boston ºtiinþifice anunta primul implant de nou dispozitiv pentru tratarea insuficienþei cardiace - Boston Scientific Announces First Implant Of New Device To Treat Heart Failure - articole medicale engleza - startsanatate